SION
Sionna Therapeutics, Inc. (SION) Business Model Analysis (2026)
Overall Score
Revenue Model
The company appears to have a simple operating model with no revenue efficiency metrics reported in the fresh data.
No material evidence of diversified or recurring revenue streams is provided in the current metrics.
Profitability
Fresh metrics show no operating or net margin generation, with EBIT margin, EBITDA margin, operating margin, pretax margin, and net profit margin all at 0.0.
Returns remain deeply negative, including ROA at -34.4%, ROE at -32.9%, and ROIC at -40.0%, indicating the business is still unprofitable.
Scalability
The fresh data does not show operating leverage, with turnover and margin metrics still at 0.0 across the income statement.
High payables days of 623.8 and a negative cash conversion cycle suggest working-capital dependence rather than scalable cash generation.
Capital Efficiency
The balance sheet remains liquid, with a current ratio of 20.0x and cash ratio of 5.9x, supporting short-term flexibility.
Capital structure is light, with debt-to-equity at 0.03x and debt-to-assets at 2.8%, but weak returns on capital offset that strength.
Valuation ratios imply the market is not assigning a premium, with price-to-book at 1.10x and price-to-fair-value at 1.10x.
Moat
The fresh metrics do not show evidence of pricing power, as gross profit margin and operating margin remain at 0.0.
There is no clear sign of durable competitive advantage in the reported operating metrics, and profitability remains negative.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Sionna Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

